⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2014Journal of Clinical OncologyOpen Access

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

Mingzhao Xing Rengyun Liu Xiaoli Liu Avaniyapuram Kannan Murugan Guangwu Zhu Martha A. Zeiger Sara I. Pai Justin A. Bishop

View Full Paper

Ask AI

Bookmark

Share

Abstract

Coexisting BRAF V600E and TERT C228T mutations form a novel genetic background that defines PTC with the worst clinicopathologic outcomes, providing unique prognostic and therapeutic implications.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xing et al. (2014) studied this question.

synapsesocial.com/papers/69d7d6d65c3030ff03d17cb7 https://doi.org/10.1200/jco.2014.55.5094

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
2KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
3Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
4Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026
5PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026

Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisJournal of Clinical Oncology · 2026
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerJournal of Clinical Oncology · 2026
Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast CancerJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Johns Hopkins University

More from Johns Hopkins Medicine